Anaplastic lymphoma kinase (ALK) mutations in patients with adenocarcinoma of the lung.
N MohamadP JayalakshmiA RhodesC-K LiamJ-L TanS YousoofPathmanathan RajaduraiPublished in: British journal of biomedical science (2017)
Detection of ALK expression by IHC is reliable and the most practical way of identifying NSCLC patients likely to benefit from crizotinib treatment.
Keyphrases
- advanced non small cell lung cancer
- end stage renal disease
- ejection fraction
- small cell lung cancer
- newly diagnosed
- squamous cell carcinoma
- diffuse large b cell lymphoma
- prognostic factors
- tyrosine kinase
- combination therapy
- binding protein
- radiation therapy
- patient reported outcomes
- rectal cancer
- patient reported
- smoking cessation
- sensitive detection